精制的ELN 2024风险分层改善了在AML治疗基于venetoclax的治疗后的生存预后
Curtis A Lachowiez1, Vishvaas I Ravikumar1, Jad Othman2,3,4
1Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Blood
|November 1, 2024
概括
新的欧洲白血病网 (European LeukemiaNet 2024) 针对用低甲基化剂和venetoclax治疗急性髓性白血病 (AML) 的指导方针已经公布. 将额外的基因突变纳入风险模型可以显著改善患者的预后,并个性化治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 急性髓性白血病 (AML) 的治疗已经通过组合疗法得到了进展.
- 风险分层对于优化AML患者管理至关重要.
- 欧洲白血病网 (ELN) 提供了针对AML预后的最新指南.
研究的目的:
- 评估将新基因突变纳入ELN 2024风险模型的影响.
- 评估使用低甲基化剂和venetoclax治疗的AML患者改善和个性化预后的潜力.
主要方法:
- 分析患者数据以根据更新的遗传标记重新分类风险.
- 预后准确度的比较,包括新突变和不包括新突变.
- 欧洲白血病网2024风险分层框架的应用.
主要成果:
- 基于新的遗传突变数据重新分类AML患者.
- 在风险分层的准确性方面有明显的改进.
- 提高个性化患者预后的能力.
结论:
- 目前的风险分层模型可以通过结合额外的基因突变来改进.
- 对接受特定治疗的AML患者进行个性化预后是可以实现的.
- 更新的基因分析增强了ELN 2024指南的实用性.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


